Bob Bohrer is a Professor of Law at California Western School of Law where he has been a member of the faculty since 1982. He was one of the first full-time law teachers in the United States to concentrate on the emerging area of biotechnology law. His current research is focused on the way in which drug development and use is influenced by a number of areas of law, including FDA approval, patent law, insurance and reimbursement, and the First Amendment commercial speech doctrine. Professor Bohrer has chaired the Biolaw Section of the AALS (2015), served on the Emerging Technology Research Advisory Committee (ETRAC), Bureau of Industry Security at the U.S. Department of Commerce (2016-2018), and the Council of the ABA Section of Science and Technology He also served on the board of directors of the Biotechnology Institute of the U.S. Patent and Trademark Office and was executive editor of Biotechnology Law Report from 1999 to 2011. He was director of Biotechnology Programs at the University of California at San Diego’s Center for Molecular Genetics, the Institutional Biosafety Committee at UCSD, and on the board of directors of the La Jolla Institute for Molecular Medicine. While in law school at Illinois, he was a member of Law Review and a teaching assistant in the College of Commerce.
Presentation (PPTX format): California Western School of Law, Deeper Mind: AI and the Future of Antibody Patents